Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
(2020) Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates
Jonscher, K
In the STEP 1 trial, semaglutide led to an average 14.9% reduction in body weight over 68 weeks , far outperforming placebo (NEJM study on semaglutide for weight loss)
The same research shows the body-composition picture still improved overall, because far more fat was lost than muscle
Their primary use was in managing type 2 diabetes by helping to control blood sugar levels after meals
Authors included David D
US$ 24.03
US$ 22.75
US$ 20.65
